Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00882076 · ClinicalTrials.gov registry record · Phase 1
Clofarabine, Etoposide, and Mitoxantrone for Relapsed and Refractory Acute Leukemias
A Phase 1 study, sponsored by Milton S. Hershey Medical Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT00882076 is a Phase 1 study that was terminated before completion, run by Milton S. Hershey Medical Center. The registered enrollment target is 22 participants.
The verdict
NCT00882076, a Phase 1 study, was terminated before completion, sponsored by Milton S. Hershey Medical Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
The purpose of this study is to establish toxicity and a maximum tolerated dose recommended phase 2 dose of Clofarabine in combination with Etoposide and Mitoxantrone for therapy of relapsed or refractory acute leukemias. The investigators will observe responses with these therapy agents and assess the impact of Clofarabine interacting with Etoposide in induction of DNA strand breaks.
Interventions
- DRUG Etoposide
- DRUG Mitoxantrone
- DRUG Clofarabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2009-03 |
| Est. Completion | 2011-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00882076
The ClinicalTrials.gov registry entry for NCT00882076 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Milton S. Hershey Medical Center, which has 396 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Etoposide is the first listed.
NCT00882076 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00882076 about?
NCT00882076 is a clinical study titled "Clofarabine, Etoposide, and Mitoxantrone for Relapsed and Refractory Acute Leukemias". The purpose of this study is to establish toxicity and a maximum tolerated dose recommended phase 2 dose of Clofarabine in combination with Etoposide and Mitoxantrone for therapy of relapsed or refractory acute leukemias. The investigators will observe responses with these therapy agents and assess ...
What is the current status of trial NCT00882076?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2009-03. Estimated completion is 2011-03.
What interventions are being tested in trial NCT00882076?
The interventions under investigation include: Etoposide (DRUG), Mitoxantrone (DRUG), Clofarabine (DRUG).
Who is sponsoring clinical trial NCT00882076?
This trial is sponsored by Milton S. Hershey Medical Center, which has 396 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.